| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c8b394197b54c5c39582a814c6bfad4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6831
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a72fe92f96b1fc6ac4822dc024a3322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dcec5507f344d10856677c459173bb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf27c39887dfa2b54cb6a8d30f70c6a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_653998cdbec41f30194983749a4e8cff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4650098d7dbf19eca76169907550a0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0421b956f6016bb6b3c70bf9f86222d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db3c107b86c8d4ea95cf4fb3e9af4f91 |
| publicationDate |
2022-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11446388-B2 |
| titleOfInvention |
Amanitin antibody conjugates |
| abstract |
The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6′-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a BCMA-binding moiety comprising (i) the variable domains of humanized antibody J22.9-ISY, and (ii) a heavy chain constant region comprising a D265C mutation; and (c) a protease-cleavable linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of multiple myeloma. |
| priorityDate |
2016-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |